A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Gastroesophageal Reflux Disease

In brief

The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression therapy, such as a Proton Pump Inhibitor (PPI).

Key facts

Study ID

NCT01161602

Run by

Edusa Pharmaceuticals, Inc.

Expected to finish

2011-05-01

Last updated by the study team

2011-09-21

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with history of Gastroesophageal Reflux Disease (GERD) symptoms (heartburn, regurgitation, acid taste in mouth).
• Between ages of 18 - 70 inclusive.
• Develop GERD symptoms following ingestion of a refluxogenic meal.
• Able to take a stable Proton Pump Inhibitor (PPI) regimen for duration of study.
• Understand and sign the informed consent form.

You may not qualify if…

• Pregnant or lactating women.
• Allergic to pumosetrag or formulation excipients.

Where it is running

• Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
• Advanced Clinical Research Institute — Anaheim, California, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Lynn Health Science Institute — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.